KUALA LUMPUR (Sept 1): OSK Ventures International Bhd's joint-venture (JV) private equity company OSK-SBI Venture Partners recently emerged as an investor of regional health tech company Doctor Anywhere (DA).

DA announced in an Aug 31 statement that the latest funding round is led by growth equity investor Asia Partners and aside from OSK-SBI Venture, it had also attracted other investors including Danish firm Novo Holdings and health technology company Philips.

It added that existing investors also participated in the round, including Singapore-based global investor EDBI, Square Peg, IHH Healthcare Bhd, Kamet Capital and Pavilion Capital — the private equity (PE) unit of Temasek.

DA said that it had closed a Series C financing round of S$88 million (US$65.7 million or about RM271.28 million), pointing out that it is one of the largest private funding rounds ever raised by a healthtech company in Southeast Asia.

The latest fundraising brings the total capital raised by DA since founding to more than S$140 million, stated the omnichannel healthcare company.

Since its launch in 2017, Singapore-headquartered DA has grown to serve more than 1.5 million users across Southeast Asia.

"Over the past 18 months, the Covid-19 pandemic also served as a catalyst to fast-track the adoption of telehealth services in the region, an innovation which enabled the healthcare industry to continue providing high-quality, affordable care to families through the crisis," DA pointed out in the statement.

DA added that it had built a "strong ecosystem" of payers, providers and patients across its core markets.

It has close to 2,800 doctors and medical professionals within its network in the region, and DA also works closely with major hospitals and healthcare institutions.

Lim Wai Mun, the founder and chief executive officer (CEO) of DA, said: “DA’s mission is to be the largest tech-enabled omnichannel healthcare provider in Southeast Asia, and applying innovative technology to improving patient outcomes is core to our differentiated offerings. We are thrilled to attract the interest of a strong group of investors in this round, a significant milestone which is a testament to our vision and track record.”

“We will utilise this funding to further enhance our digital capabilities, and scale up our ability to deliver quality healthcare seamlessly to our users in Southeast Asia,” added Lim.